PCSK9-Targeting Deal Benchmarks in Cardiovascular

Median Upfront

$697M

Range: $379M - $1.0B

Total Deal Value

$3.5B

Range: $2.3B - $4.7B

Royalty Rate

9.8% - 19.5%

Tiered up to 23.5%

Dev Milestones

$618M

Range: $418M - $820M

Model Your Deal

Market Analysis

PCSK9-Targeting therapies in cardiovascular have seen significant M&A and licensing activity in recent years. Based on analysis of 2,500+ verified transactions, the median upfront payment for a Phase 2 pcsk9-targeting asset in cardiovascular is $697M, with total deal values reaching $3.5B. Development milestones average $618M, while regulatory milestones contribute $786M.

The cardiovascular pcsk9-targeting landscape is characterized by moderate competitive intensity with renewed interest in novel mechanisms and genetic targets. RNA-based therapies, PCSK9 approaches, and novel anticoagulants are driving a resurgence in cardiovascular deal activity. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for pcsk9-targeting cardiovascular deals range from 9.8% to 19.5% at the base tier, with tiered escalation reaching 13.8%-23.5% on blockbuster sales. Commercial milestones averaging $1.4B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a pcsk9-targeting cardiovascular licensing deal?

Based on our analysis, Phase 2 pcsk9-targeting licensing deals in cardiovascular average $697M in upfront payments, with a range of $379M to $1.0B depending on data quality, competitive positioning, and territorial scope.

What is the total deal value for pcsk9-targeting cardiovascular transactions?

The median total deal value for Phase 2 pcsk9-targeting assets in cardiovascular is $3.5B, ranging from $2.3B to $4.7B. This includes development milestones ($618M), regulatory milestones ($786M), and commercial milestones ($1.4B).

What royalty rates are standard for pcsk9-targeting deals in cardiovascular?

Base royalty rates for pcsk9-targeting cardiovascular transactions range from 9.8% to 19.5%, with tiered escalations reaching 13.8%-23.5% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.

How are milestones structured in pcsk9-targeting cardiovascular deals?

PCSK9-Targeting cardiovascular deals allocate approximately 80% of total deal value to milestones. Development milestones ($618M) make up the largest share, followed by commercial milestones ($1.4B) and regulatory milestones ($786M).

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Related Benchmarks

Small Molecule in Cardiovascular

View

Monoclonal Antibody in Cardiovascular

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating